Check Out New Amanita Muscaria Mushroom-Based Products By Lucy Scientific Discovery
Health Canada-licensed psychedelics company Lucy Scientific Discovery Inc. (NASDAQ: LSDI) is joining a growing number of businesses offering Amanita Muscaria
Enveric Releases Paper Detailing The Development Of Novel Psilocin Prodrugs For The Treatment Of Mental Health Disorders
Enveric Biosciences, Inc. (NASDAQ: ENVB) has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders. A manuscript describing the research has been submitted for peer-reviewed publication and is currently
MindMed’s LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected
MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed.
The Flaming Lips, Eric Andre & Reggie Watts And Many More At MAPS 2023 Psychedelic Event
MAPS’ Psychedelic Science 2023 is taking place this June in Denver.
Canadian Psychedelics Company And Nonprofit Team Up To Accelerate Access And Product Launch
Health-Canada licensed psychedelics biotech Lucy Scientific Discovery (NASDAQ: LSDI) and not-for-profit psilocybin advocate organization TheraPs
Enveric Biosciences Receives Notice Of Allowance From US Patent And Trademark Office For Novel Prodrug Of Psilocin
Enveric Biosciences, Inc. (NASDAQ: ENVB) has received a notice of allowance from the United States Patent and Trademark Office for a patent application involving EB-373, th
The Psychedelic Mushrooms Market; Between Legitimate Harvesting And Illegal Retail Sales
While psychedelics reform is clearly gaining momentum, not only in the U.S. but notably in places like Australia and less so Canada. The fact is, all compounds remain currently Schedule I drugs (or equivalents) and thus federally illegal in many countries including the U.S.
African Iboga Root Heads To Canadian Company Developing Natural Drugs To Help Treat Addictions
Clinical-stage natural psychedelics company Filament Health Corp. (OTCQB: FLHLF) has completed the first-ever Nagoya Protocol-compliant import of Tabernanthe iboga root from Gabon to the company’s R&D Vancouver facility.
Mydecine’s Q1 2023 Reports Shows Decline In Assets And R&D, Increase In Net Loss And Accumulated Deficit
Psychedelics biotech Mydecine Innovations Group (OTC: MYCOF) shared its condensed interim (unaudited) financial results for three months ended March 31, 2023.
First quarter numbers:
Seelos Therapeutics Positive Q1 Financials Make For ‘The Most Important Year’ In Company’s History
Clinical-stage biopharma company Seelos Therapeutics Inc. (NASDAQ: SEEL) reported financial results and clinical updates corresponding to the first quarter ended March 31, 2023.
Quarterly numbers show: